CS-121 APOC3 Base Editing in FCS
Key facts
- Who runs it
- CorrectSequence Therapeutics Co., Ltd
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 15 people, planned
- Started
- 15 Oct 2025
- Expected to end
- Dec 2026
- Type of study
- Interventional, 5 groups
- Treatments tested
- CS-121
- Record updated
- 11 February 2026
Who can take part
- Age
- 18 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Male or female aged 18 to 55 years (inclusive) at the time of signing informed consent
- On regular standard therapy with good compliance, but fasting triglyceride (TG) levels have not been consistently reduced below 10 mmol/L (880 mg/dL); i.e., before screening, there must be records of at least three separate fasting TG values >10 mmol/L (880 mg/dL), or the participant is intolerant to standard therapy
- North American Familial Chylomicronemia Syndrome (NAFCS) score ≥45
- Able to sign informed consent and comply with the requirements and restrictions specified in the informed consent form and the protocol, such as dietary guidance and intake restrictions
- Female participants must meet one of the following: be not of childbearing potential (e.g., documented hysterectomy, bilateral salpingectomy/sterilization, or ≥1 year postmenopausal); or, if of childbearing potential, have a negative pregnancy test at screening and be willing to use strict and effective contraception (e.g., abstinence, pharmacologic, or barrier methods) during the study. Male participants with reproductive potential must agree to use strict and effective contraception (e.g., abstinence, pharmacologic, or barrier methods) throughout the entire post-dose observation period; males without reproductive potential must provide supporting medical history (e.g., post-vasectomy)
Who cannot take part
- Currently participating in another interventional clinical study, or last use of another investigational product with a washout period of less than 5 half-lives or 30 days (whichever is longer)
- Use of APOC3-targeted antisense oligonucleotides (ASO) or siRNA lipid-lowering agents within 6 months prior to dosing
- History of acute pancreatitis within 3 months before dosing
- History of acute coronary syndrome (ACS) within 6 months before dosing, such as myocardial infarction or unstable angina, or prior coronary revascularization (e.g., coronary artery bypass grafting, angioplasty, or stent implantation)
- In the investigator's judgment, receipt of major surgery within 3 months before dosing that would make the participant unsuitable for this study drug or unable to tolerate possible cytokine-release events
- Concomitant medications or treatments judged by the investigator to affect lipid metabolism, hepatic or renal function, or coagulation, or to interfere with the evaluation of study drug efficacy, including but not limited to: systemic glucocorticoids, anabolic steroids, antiretroviral agents used within 4 weeks prior to dosing, plasma exchange, blood donation, or blood loss >200 mL
- Positive at screening for HBsAg, HCV antibody and RNA, HIV, or Treponema pallidum (syphilis)
- Known major organ disease, psychiatric disorders, Cushing's syndrome, or malignancy that, in the investigator's judgment, would make the participant unsuitable for the study or unable to tolerate possible cytokine-release-like events
- Any of the following laboratory abnormalities at screening:; ALT or AST ≥3 × ULN Total bilirubin ≥1.5 × ULN eGFR <30 mL/min/1.73 m² Random urine albumin-to-creatinine ratio (UACR) >30 mg/g LDL-C >130 mg/dL (3.4 mmol/L) HbA1c ≥9%
- Coagulation abnormalities deemed by the investigator to make CS-121 administration unsuitable
- Planning pregnancy, currently pregnant, or breastfeeding
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is an open-label, single-arm, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid nanoparticles targeting APOC3, in adult participants (18-55 years) with familial chylomicronemia syndrome (FCS).
The 5 groups in the trial
- Single Low Dose CS-121Treatment being tested
Participants in this arm will receive a single low dose of CS-121.
Treatment: CS-121
- Single Middle Dose CS-121Treatment being tested
Participants in this arm will receive a single middle dose of CS-121.
Treatment: CS-121
- Single High Dose CS-121Treatment being tested
Participants in this arm will receive a single high dose of CS-121.
Treatment: CS-121
- Single Lower Dose 1 of CS-121Treatment being tested
Participants in this arm will receive a single lower dose 1 of CS-121.
Treatment: CS-121
- Single Lower Dose 2 of CS-121Treatment being tested
Participants in this arm will receive a single lower dose 2 of CS-121.
Treatment: CS-121
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of CS-121, an In Vivo Base Editing Therapy Delivered by Lipid Nanoparticles Targeting APOC3, in Adults With Familial Chylomicronemia Syndrome
- Criteria questions
- Built from NCT07176923, who can take part
- Record updated
- 11 February 2026